CTRI/2009/091/000238已完成3 期
A Multi-Center, Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With Vildagliptin (50 mg qd and 100 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
ovartis Healthcare Private Limited0 个研究点目标入组 300 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •History T2DM
- •Moderate or Severe Renal Impairment
排除标准
- •Glucose > 270 mg/dL (>15 mmol/L)
研究者
相似试验
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiencyEUCTR2007-003723-21-DEovartis Pharma Services AG525
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiency - NDEUCTR2007-003723-21-ITOVARTIS FARMA300
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiencyDiabetes Type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-003723-21-FIovartis Pharma Services AG300
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiencyDiabetes Type 2EUCTR2007-003723-21-SEovartis Pharma Services AG525
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiencyEUCTR2007-003723-21-FRovartis Pharma Services AG300